Noul Co. Ltd. announced that it has signed an agreement with The RIGHT Foundation to conduct a global clinical studies to determine the potential for public market access in malaria-endemic countries of Africa and Asia. Over the next three years, about four billion KRW (USD 3.1 million) that Noul received from The RIGHT Foundation will be used to support global clinical studies and cost-effectiveness analysis of the miLab™.

To ensure the credibility of the result, Noul will collaborate with global institutions and national malaria programs such as PATH (Program for Appropriate Technology in Health), Swiss TPH (Swiss Tropical and Public Health Institute), GIDC (Ghana Infectious Disease Center), MNMCP(Malawi National Malaria Control Program) and University of Notre Dame in the U.S. Malaria is a disease with a high demand for diagnosis, affecting more than 200 million people yearly. It has recently been facing great difficulties in diagnosis due to the increase of genetic mutations that are difficult to diagnose with existing RDT, and drug resistance problem. Through agreement, Noul and The RIGHT Foundation will conduct multi-country clinical studies to compare the diagnostic accuracy of the miLab™ with the result of the microscopic diagnosis and PCR analysis.

Also, both parties will analyze the value and cost-effectiveness of the miLab™ in the global healthcare market, and accelerate public market entry through local registration.